非酒精性脂肪性肝病患者健康相关生活质量:一项前瞻性多中心英国研究
该前瞻性多中心英国研究纳入513例非酒精性脂肪性肝病(NAFLD)患者,采用倾向性评分1:1匹配与2018年英格兰健康调查普通人群子队列(n=5483)比较。结果显示NAFLD患者EQ-5D-5L效用值显著低于匹配对照(0.77±0.27 vs 0.84±0.19,P<.001),即使无晚期纤维化者亦如此;无晚期纤维化者生活质量与代谢合并症相关而非肝硬度。
要点
- NAFLD患者健康相关生活质量较普通人群显著降低,无晚期纤维化者亦存在损害。
- 有无晚期纤维化者之间健康相关生活质量指标无显著差异。
- 无晚期纤维化者生活质量与女性、2型糖尿病和抑郁独立相关,与肝硬度无关。
核心结论
- NAFLD患者即使无晚期纤维化,健康相关生活质量也较普通人群差。
- 无晚期纤维化NAFLD患者的生活质量与肝脏外合并症独立相关,与肝硬度无关。
- 因此无论纤维化严重程度,NAFLD均需要多学科管理。
研究设计与样本
- 前瞻性多中心英国研究,连续纳入513例NAFLD患者并完成EQ-5D及慢性肝病问卷(CLDQ)。
- 记录人口学与临床信息、肝活检结果和/或瞬时弹性成像肝硬度(LS)。
- 以2018年英格兰健康调查普通人群子队列(n=5483)为对照,按年龄、性别、体质指数和2型糖尿病(T2DM)进行1:1倾向性评分匹配。
主要发现
- 466例倾向性评分匹配的NAFLD患者EQ-5D-5L效用值显著低于匹配对照(0.77±0.27 vs 0.84±0.19,P<.001)。
- 无晚期纤维化(F≤2或LS<8kPa)者EQ-5D-5L效用值也显著低于匹配对照(0.80±0.24 vs 0.84±0.19,P=.024)。
- 有无晚期纤维化的NAFLD患者之间EQ-5D-5L、EQ-VAS和CLDQ均无显著差异。
- 在所有NAFLD患者中LS与较低EQ-5D-5L独立相关,但在无晚期纤维化者中无此关联。
- 无晚期纤维化者中,较低EQ-5D-5L与女性、T2DM和抑郁相关。
临床怎么用
- 原文结论提出无论纤维化严重程度,NAFLD均需要多学科管理。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND & AIMS: It is unclear whether health-related quality of life (HRQoL) is impaired in patients with nonalcoholic fatty liver disease (NAFLD) without advanced fibrosis and how this compares with the general population. We aimed to assess HRQoL in patients with NAFLD in comparison to the general population and any associations of fibrosis severity and metabolic comorbidities with impairments in HRQoL. METHODS: We prospectively enrolled 513 consecutive patients with NAFLD who completed the EuroQol 5-dimensional questionnaire (EQ-5D) and Chronic Liver Disease Questionnaires (CLDQ). Demographic and clinical information, liver biopsy results, and/or liver stiffness (LS) by transient elastography were recorded. A general population sub-cohort of the Health Survey for England 2018 was used as a comparator (n = 5483), and a 1:1 propensity-score (PS) matching was performed, according to age, sex, body mass index, and type 2 diabetes mellitus (T2DM). RESULTS: EQ-5D-5L utility was significantly lower in 466 PS-matched patients with NAFLD compared with PS-matched controls (0.77 ± 0.27 vs 0.84 ± 0.19; P < .001), even in those without advanced fibrosis (F ≤2 or LS <8kPa) (0.80 ± 0.24 vs 0.84 ± 0.19; P = .024). HRQoL measures (EQ-5D-5L, EQ-VAS, CLDQ) did not differ between patients with NAFLD with and without advanced fibrosis. LS was independently associated with lower EQ-5D-5L in all patients with NAFLD but not in those without advanced fibrosis. In the latter, lower EQ-5D-5L was associated with female sex, T2DM, and depression. CONCLUSIONS: Patients with NAFLD, even those without advanced fibrosis, have worse HRQoL compared with the general population. In patients with NAFLD without advanced fibrosis, HRQoL is independently associated with non-liver comorbidities but not LS. Multi-disciplinary management is therefore required in NAFLD, irrespective of fibrosis severity.
引用
- Papatheodoridi M, Pallini G, Aithal G, et al. Health-related Quality of Life in Patients With Nonalcoholic Fatty Liver Disease: A Prospective Multi-center UK Study. Clin Gastroenterol Hepatol. 2023. PMID: 37880933. doi:10.1016/j.cgh.2023.04.018
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。